Pacira BioSciences, Inc. (PCRX) P/E Ratio History
Fairly ValuedTrading at 139.6x, near 5Y avg of 139.7x · 70th percentile · In line with own history · Data 2015–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Pacira BioSciences, Inc. (PCRX) trades at a price-to-earnings ratio of 139.6x, with a stock price of $22.33 and trailing twelve-month earnings per share of $0.23.
The current P/E is roughly in line with its 5-year average of 139.7x. Over the past five years, PCRX's P/E has ranged from a low of 15.5x to a high of 889.5x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, PCRX trades at a 531% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, PCRX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PCRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PCRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PCRX P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 11.1Lowest | - | +431% | |
| $1B | 26.8 | 3.58 | +1883%Best | |
| $8B | 26.8 | 1.17Best | -25% | |
| $102B | 22.0 | - | +31% | |
| $118B | 36.6 | 2.46 | +8% | |
| $17B | 24.8 | - | -20% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PCRX Historical P/E Data (2015–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $22.60 | $0.12 | 188.3x | -23% |
| FY2025 Q4 | Dec 31 2025 | $25.88 | $0.15 | 172.5x | -29% |
| FY2025 Q3 | - | $25.77 | $0.45 | 57.3x | -76% |
| FY2024 Q2 | Jun 30 2024 | $28.61 | $1.29 | 22.2x | -91% |
| FY2024 Q1 | Mar 31 2024 | $29.22 | $1.41 | 20.8x | -91% |
| FY2023 Q4 | Dec 31 2023 | $33.74 | $0.79 | 42.8x | -82% |
| FY2023 Q3 | Sep 30 2023 | $30.68 | $0.09 | 340.9x | +40% |
| FY2022 Q4 | Dec 31 2022 | $38.61 | $0.31 | 124.5x | -49% |
| FY2022 Q3 | Sep 30 2022 | $53.19 | $0.41 | 129.7x | -47% |
| FY2022 Q2 | - | $58.30 | $0.82 | 71.1x | -71% |
| FY2022 Q1 | - | $76.32 | $0.84 | 90.9x | -63% |
| FY2021 Q4 | Dec 31 2021 | $60.17 | $0.92 | 65.4x | -73% |
| FY2021 Q3 | - | $56.00 | $1.36 | 41.2x | -83% |
| FY2021 Q2 | Jun 30 2021 | $60.68 | $3.91 | 15.5x | -94% |
| FY2021 Q1 | Mar 31 2021 | $70.09 | $3.32 | 21.1x | -91% |
| FY2020 Q4 | - | $59.84 | $3.28 | 18.2x | -92% |
| FY2020 Q3 | Sep 30 2020 | $60.12 | $2.84 | 21.2x | -91% |
| FY2019 Q3 | Sep 30 2019 | $38.07 | $0.04 | 889.5x | +266% |
| FY2019 Q2 | Jun 30 2019 | $43.49 | $0.18 | 245.4x | +1% |
| FY2019 Q1 | Mar 31 2019 | $38.06 | $0.18 | 214.8x | -12% |
| FY2015 Q4 | - | $76.79 | $0.04 | 1815.4x | +647% |
| FY2015 Q3 | Sep 30 2015 | $41.10 | $0.25 | 164.3x | -32% |
| FY2015 Q2 | - | $70.72 | $0.09 | 816.6x | +236% |
Average P/E for displayed period: 243.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
What is PCRX's P/E ratio?
Pacira BioSciences, Inc. (PCRX) trailing twelve-month P/E ratio is 139.6x, based on TTM diluted EPS of $0.23. The 5-year average P/E is 139.7x and the historical range spans 15.5x to 889.5x.
Is PCRX stock overvalued or undervalued?
PCRX trades at 139.6x P/E, near its 5-year average of 139.7x. The 70th percentile ranking within the 15.5x–889.5x historical range places valuation within normal bounds.
Is PCRX stock expensive?
PCRX is fairly valued relative to its own history. The current P/E of 139.6x is near the 5-year average of 139.7x (70th percentile of historical range).
What is PCRX's historical P/E range?
Over the past 5 years, PCRX's P/E ratio has ranged from 15.5x to 889.5x, with a median of 71.1x and an average of 139.7x. The current P/E of 139.6x places the stock at the 70th percentile of this range. Full historical data spans 2015–2026.
How does PCRX's P/E compare to the S&P 500?
PCRX trades at 139.6x P/E versus the S&P 500 median of 24.4x. The 472% premium to the market typically reflects higher expected earnings growth or quality.
How does PCRX's valuation compare to Healthcare peers?
Pacira BioSciences, Inc. P/E of 139.6x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PCRX's PEG ratio?
PCRX PEG ratio is N/A, based on a P/E of 139.6x and EPS growth of 107.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PCRX's earnings yield?
PCRX earnings yield is 0.72%, the inverse of its 139.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.